Richard A. F. Dixon
Fundador en 7 Hills Pharma LLC .
Perfil
Richard A.
F.
Dixon is the founder of 7 Hills Pharma LLC.
Prior to founding 7 Hills Pharma LLC, he worked as the Chief Scientific Officer & SVP-Research at Encysive Pharmaceuticals, Inc. from 1990 to 2011.
Before that, he was the Director & Head-Molecular Biology at Merck Sharp & Dohme Research Laboratories from 1988 to 1990.
Dixon received his undergraduate degree from Texas A&M University and his doctorate from Baylor College of Medicine.
Cargos activos de Richard A. F. Dixon
Empresas | Cargo | Inicio |
---|---|---|
7 Hills Pharma LLC
7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Fundador | - |
Antiguos cargos conocidos de Richard A. F. Dixon.
Empresas | Cargo | Fin |
---|---|---|
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Director Técnico/Científico/I+D | 29/04/2011 |
Merck Sharp & Dohme Research Laboratories | Director/Miembro de la Junta | 01/01/1990 |
Formación de Richard A. F. Dixon.
Texas A&M University | Undergraduate Degree |
Baylor College of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Health Technology |
Merck Sharp & Dohme Research Laboratories | |
7 Hills Pharma LLC
7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Richard A. F. Dixon